MULSHINE BRENDAN MARTIN sold $1.6M of RYAN

MULSHINE BRENDAN MARTIN (Co-President and CRO) sold 40,000 shares of RYAN SPECIALTY HOLDINGS, INC. (RYAN) at $40.51 ($1.62M total) on 2026-09-08.

Original reporting
SEC EDGAR · MULSHINE BRENDAN MARTIN
Published Sep 9, 2026, 9:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RYAN
Bearish
medium confidence
Mentioned
$RYAN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RYANBearishLow
01

Why it matters

The disclosed sale may lead to short-term price weakness, but the overall impact is limited given the modest size relative to market cap.

02

Market read

Primary insider sale provides new information for traders monitoring RYAN.

03

What to watch

No indication of upcoming earnings or corporate events that might explain the sale.

Relevance 6/10Novelty 6/10Timing: post-market 2026-09-08

Background

Form 4 filings disclose insider transactions and are used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$RYANBearishMedium confidence
Context

Co-President Brendan Martin sold 40,000 shares for $1.62M on 2026-09-08, reducing his stake to 75,366 shares.

Expected impact

Possible modest downside pressure in the next trading session.

Evidence & confidence

Sale size is moderate ($1.6M) and the insider holds a senior role, which can influence market perception.

Market effects

Minimal; the sale does not affect the broader specialty chemicals sector.

Limited to U.S. investors tracking insider activity.

Low

Counterpoint

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Brendan Martin

    Co-President and Chief Risk Officer of Ryan Specialty Holdings.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RYANMed

Ryan Specialty Holdings Inc (RYAN) (Q3 2026) Earnings Call Highlights: Revenue Growth

Ryan Specialty Holdings (RYAN) reported Q3 2026 revenue growth slowing to 4% from 15% YoY, with adjusted EBITDAC margin down 30 bps to 30.9%. The company cited market challenges, including property pricing declines and increased competition. Management expects continued pressure in Q4 2026 and 2027, with modest margin expansion anticipated. They also discussed growth opportunities in reinsurance and AI-related risks, and potential M&A activity in 2027.

Med

Ryan Specialty grows revenue as property softening squeezes E&S returns

Ryan Specialty reported a 4.7% revenue increase to $790M in Q3 2026, driven by casualty lines, while property revenue declined. Underwriting management grew 5.4%, expanding its share of total revenue. Expenses rose 9.9%, outpacing revenue growth. The company maintained its full-year guidance for mid-single-digit organic revenue growth and reported a 3.8% increase in adjusted EBITDAC to $244.4M.